Press Releases

ThermoGenesis Holdings to Postpone Third Quarter 2019 Earnings Release and Conference Call Until Tuesday November 19, 2019

RANCHO CORDOVA, Calif., Nov. 14, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO) formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced it will delay its third quarter ended September 30, 2019 earnings release and subsequent earnings conference call, previously scheduled for … Continued

ThermoGenesis Holdings to Delay Third Quarter 2019 Earnings Release and Conference Call Until Thursday November 14, 2019

RANCHO CORDOVA, Calif., Nov. 12, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), formerly known as Cesca Therapeutics Inc., a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced  it will delay its third quarter ended September 30, 2019 earnings release and conference call, previously scheduled for today, … Continued

ThermoGenesis Holdings to Announce Financial Results for the Third Quarter Ended September 30, 2019 and Provide a Corporate Strategic Update

Conference Call to be Held on November 12, 2019 RANCHO CORDOVA, Calif., Nov. 6, 2019 — ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing for regenerative medicine, today announced that the Company will release its financial results for the third quarter ended September 30, 2019 and provide a strategic corporate update on Tuesday, … Continued

Cesca Therapeutics to Change Name and Ticker Symbol to Reflect New Strategic Focus

ThermoGenesis to Focus on Developing Automated Cell Processing Tools and Services for the Cell and Gene Therapy Field RANCHO CORDOVA, Calif., Oct. 31, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing for regenerative medicine, today announced that the company will change its name to ThermoGenesis Holdings, Inc. (“ThermoGenesis”) in … Continued

Cesca Therapeutics to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference

RANCHO CORDOVA, Calif., Oct. 24, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Chris Xu, Ph.D., Chairman and Chief Executive Officer, will present a company overview at the Dawson James Securities 5th Annual Small Cap Growth Conference at the Wyndham Grand Hotel in Jupiter, Florida on Tuesday October 29, at 12:45 pm ET. Management will … Continued

Cesca Therapeutics Forms Joint Venture with HealthBanks Biotech (USA) to Provide Immune Cell Banking and Cell Processing Services

ImmuneCyte to Begin Operations in Fourth Quarter of 2019   RANCHO CORDOVA, Calif., Oct. 21, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary, today announced that the company has entered into a definitive joint venture … Continued

Cesca Therapeutics to Present at the 2019 BIO Investor Forum

RANCHO CORDOVA, Calif., October 14, 2019 — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, today announced Jeff Cauble, Vice President of Finance and Principal Accounting Officer, will present at the 2019 BIO Investor Forum on Tuesday, October 22 at 4:00 pm PT. The … Continued

Cesca Therapeutics Announces Receipt of $2 Million Upfront Distribution Fee

RANCHO CORDOVA, Calif., October 2, 2019 – Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), announced today it has received the $2 million upfront distribution fee pursuant to its global distribution agreement, entered into as … Continued

ThermoGenesis Reports Performance Evaluations of X-Series® Cell Processing Devices

RANCHO CORDOVA, Calif., Sept. 25, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), today reported Validations of System Performance for their X-Series® products from two prestigious academic medical centers:  Marcus Center for … Continued

Cesca Therapeutics And ThermoGenesis Announce Major Global Distribution Agreement For The Company’s X-Series® Products

RANCHO CORDOVA, Calif., Sept. 9, 2019 /PRNewswire/ — Cesca Therapeutics Inc. (Nasdaq: KOOL), a market leader in automated cell processing and autologous cell therapies for regenerative medicine, and ThermoGenesis, its wholly owned device subsidiary (the “Company”), filed a Form 8-K last Friday with the Securities and Exchange Commission announcing the signing of an exclusive, global … Continued

© 2019 ThermoGenesis Corp.
How may we help?